Seedlabs

Diagnosed-but-Untreated: ADHD Treatment-Gap Outreach for Health Plans

A system for health plans to find children with an ADHD diagnosis who aren't getting any treatment.

A tool for health plans and pediatric systems that finds children who already have an ADHD diagnosis but are receiving no treatment for it, then sends guideline-matched outreach to get care started.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderHealth plan and pediatric delivery-system quality improvement / population health

Concept

A population-health analytics tool that cross-references ADHD diagnosis codes against pharmacy fills and behavioral-treatment claims to identify children with current ADHD who show no ADHD-specific treatment activity in the past 12 months. For each flagged child, it generates a clinician-reviewed outreach packet matched to guideline options — medication evaluation (especially for moderate/severe cases), behavioral treatment, or parent training — with a tracked follow-up loop until treatment starts or the family declines. The untreated rate becomes a standing quality dashboard the plan or system can act on quarterly. The single wedge is converting a measured, addressable gap into treatment initiation.

Why now

The 2022 National Survey of Children's Health quantifies the gap precisely: 6.5 million US children (10.5%) have current ADHD, yet 30.1% received no ADHD-specific treatment in the past year; only 53.6% received medication and 44.4% behavioral treatment, while 58.1% were moderate/severe, 77.9% had a co-occurring disorder, and about 1 million more children were ever-diagnosed than in 2016 [1]. The European ADHD Guidelines Group confirms effective, guideline-concordant options exist (methylphenidate has the best combined efficacy/tolerability profile in children and adolescents) and names improving access to care across healthcare systems as a priority [4], while the pharmacotherapy review shows available medications deliver relatively large short-term effect sizes with good tolerability [2]. The bottleneck is therefore neither diagnosis nor drug efficacy — it is treatment initiation, which is exactly what this tool attacks with data plans already hold.

Written by GLM · 8 Oct 2026

AI assessment

Backed by 3 papers93

A high-utility population health tool that leverages existing claims data to close a quantified treatment gap, offering a clear ROI for health plans via quality metrics.

Evidence strength
5/5
The idea is directly supported by the 2022 NSCH data quantifying a 30.1% treatment gap among diagnosed children, and the EAGG guidelines provide the clinical logic for the outreach packets.
Market pull
5/5
Health plans and pediatric systems have strong financial and regulatory incentives (e.g., NCQA HEDIS-like metrics) to close care gaps and improve population health outcomes.
Novelty & moat
3/5
While it differs from the 'Diagnostic Gap' idea by focusing on treatment rather than diagnosis, it uses a similar records-mining mechanism; however, it targets a different stage of the patient journey.
Feasibility
5/5
The tool relies on standard healthcare data (ICD codes and pharmacy claims) and basic outreach workflows, making it highly buildable with a small team.
Wedge clarity
5/5
The wedge is extremely sharp: identify a specific, untreated cohort and track the conversion rate to treatment initiation.
Simplicity / focus
5/5
The product is a single-purpose analytics and outreach tool with a clear input (claims data) and output (treatment initiation).

Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Kaiser Permanentecompany

    Its integrated EHR and pharmacy data across millions of pediatric members is exactly the input the tool needs, and closing a measured ~30% untreated gap is a direct quality and outcomes win.

  • Geisingercompany

    The data-driven health system could feed flagged untreated children directly into its existing care-management outreach machinery with minimal new workflow.

  • Ohio Department of Medicaidorganization

    Medicaid programs cover a disproportionate share of children with ADHD; identifying diagnosed-but-untreated members is a concrete, measurable lever for improving child behavioral health outcomes.

  • National Committee for Quality Assurance (NCQA)organization

    NCQA could adapt the diagnosed-but-untreated rate into a plan-level quality measure, giving payers a standardized incentive to adopt the tool.

Research it builds on

  1. ADHD Prevalence Among U.S. Children and Adolescents in 2022: Diagnosis, Severity, Co-Occurring Disorders, and Treatment
    Melissa L. Danielson, Angelika Hartl Claussen, Rebecca H. Bitsko et al. · 2024 · 332 citations
    All ideas from this paper →
  2. Evidence-based pharmacological treatment options for ADHD in children and adolescents
    Konstantin Mechler, Tobias Banaschewski, Sarah Hohmann et al. · 2021 · 296 citations
    All ideas from this paper →
  3. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)
    David Coghill, Tobias Banaschewski, Samuele Cortese et al. · 2021 · 178 citations
    All ideas from this paper →
Leave feedback
feasibility